S100B and myeloid sarcoma: In EAE mice, inhibition of S100B activity using PTM [49] induced amelioration of clinical scores coherently accompanied by amelioration of pathological/biomolecular parameters, thus offering in vivo evidence that S100B plays a crucial role in pathogenic processes of MS.